LRMR
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. (LRMR) has 5 SEC Form 4 filings (8 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 8, 2026.
Insiders have net bought $25.7M over the trailing 6 months. The largest single insider purchase in this window was $25.0M by Director, 10% Owner Flynn James E on Feb 27, 2026.
- Industry:Biotechnology
- CEO:Carole S. Ben-Maimon
- Employees:71
- HQ:Bala Cynwyd, PA, US
- IPO:2014-06-19
Insider Buying
$25.7M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$432.2M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Hamilton Thomas EdwardFirst in 4 months | Director | Purchase | 50,000 | $167K | Jul 8 | SEC ↗ |
Flynn James EFirst filing | * Director by Deputization | Purchase | 5,000,000 | $25.0M | Mar 2 | SEC ↗ |
THOMAS FRANK EFirst filing | Director | Purchase | 5,000 | $25K | Mar 2 | SEC ↗ |
SHERMAN JEFFREY WFirst filing | Director | Purchase | 5,000 | $25K | Mar 2 | SEC ↗ |
Hamilton Thomas EdwardFirst filing | Director | Purchase | 100,000 | $500K | Mar 2 | SEC ↗ |
Related companies
Larimar Therapeutics, Inc. is in the Healthcare sector.